Methods We screened 463 epigenetic regulatory genes using a siRNA library in a high-throughput ISRE-luciferase assay. Q-PCR and Western blot were used to study the function of targeted genes.

Results Among those genes which significantly enhanced or inhibited ISRE activity, CDK1 had a differential expression in PBMCs and renal biopsies between SLE patients and healthy controls and was positively correlated with "IFN scores" and disease activities of SLE patients. We revealed that the expression of ISGs and phosphorylation of STAT1 could be reduced by knocking down CDK1, while over-expression of CDK1 produced an opposite effect. As specific inhibitors of IFN pathway has emerged as a promising treatment for SLE and CDK1 inhibitors are being on trial for some types of cancer, we wondered whether CDK1 inhibitor could be a potential repositioning drug for SLE. We found a CDK1 inhibitor, RO-3306, could alleviate FN in PBMCs from 5 SLE patients who had high IFN scores. We found that RO-3306 significantly reduced ISGs expression in these cells. Our preliminary data further showed that RO-3306 could reduce proteinuria in SLE mouse model.

Conclusions We proposed that CDK1 is a novel positive regulator of IFN signalling pathway, over-expression of CDK1 in SLE might contribute to the over-activated IFN signalling and inhibition of CDK1 could be used to interfere abnormal IFN signalling in SLE.

24

A MOLECULAR SIGNATURE BASED ON IFN GENE SIGNATURE AND SEROLOGY DEFINES TWO POPULATIONS OF PATIENTS WITH DIFFERENT BASELINE DISEASE ACTIVITY

¹M Petri*, ²K Kalunian, ³M Urowitz, ⁴R Furie, MA Morgan-Cox⁵, ⁶M Silk, ⁷E Dow, ⁵R Higgs, ⁵S Watts, ⁸D Isenberg, ⁹M Linnik. ¹Johns Hopkins University School of Medicine, Rheumatology, Baltimore, USA; ²University of California- San Diego School of Medicine, Rheumatology, San Diego, USA; ³University of Toronto Faculty of Medicine, Rheumatology, Toronto, Canada; ⁴Hofstra North Shore-LIJ School of Medicine, Rheumatology, Great Neck, USA; ⁵Eli Lilly, Statistics, Indianapolis, USA; ⁶Eli Lilly, Immunology, Indianapolis, USA; ⁷Eli Lilly, Bioinformatics, Indianapolis, USA; ⁸University College London, Rheumatology, London, UK; ⁹Lilly Biotechnology Centre, Immunology, San Diego, USA

10.1136/lupus-2017-000215.24

Background and Aims Randomised controlled trials in SLE have shown that response to treatment is influenced by baseline disease activity. The current investigation used objective molecular and biochemical baseline parameters to characterise SLE patients in two large multinational trials (n=2262 patients).

Methods Patients were categorised with four dichotomous baseline parameters. SLE(+) was defined by any of the following: IFN signature (high), anti-dsDNA (+), C3 (low) and/or C4 (low). SLE(-) required all of the following: IFN signature (normal), anti-dsDNA (-), C3 (normal) and C4 (normal).

Results Baseline RNA transcript data were available for 1747 of 2262 patients. When IFN status was combined with the serology criteria, 1500 (86%) were classified as SLE(+) and 247 (14%) were classified as SLE(-). At baseline, SLE(-) patients had significantly lower mean SLEDAI scores (8.3) compared to SLE(+) (10.7). Baseline SLEDAI <10 was observed in 72% of SLE(-) compared to 38% of SLE(+). The proportion on corticosteroids at baseline was 49% in SLE(-) compared to 78% in SLE(+); the proportion on immunosuppressants at baseline was 31% in SLE(-) compared to 44% in

SLE(+). In the US, 22% were SLE(-) compared to 10% for Latin America, 7% for Europe, and 5% for ROW.

Conclusions A subset of clinical trial patients was identified using biochemical and molecular markers with high sensitivity for SLE. Seronegative SLE patients with normal IFN gene signature had lower disease activity and were taking less background medication at baseline, two factors which have been negatively associated with response to treatment in some previous trials.

25

STIMULATOR OF INTERFERON GENES (STING) PLAYS A CRUCIAL ROLE IN TYPE-I IFN PRODUCTION INDUCED BY THE SERA FROM SLE PATIENTS

Y Kato*, A Kumanogoh, H Takamatsu, J Park. Osaka University, Dept. of Respiratory Medicine- Allergy and Rheumatic Disease- Graduate School of medicine, Suita- Osaka, Japan

10.1136/lupus-2017-000215.25

Background and Aims Type-I interferon (IFN-I) plays important roles in the pathogenesis of SLE. It has been reported that serum IFN-I levels are high in active SLE patients and that IFN-I is produced when DNA sensors recognise DNA-containing immune complex. Stimulator of interferon genes (STING) is known as a key molecule in cytosolic DNA-sensing, which leads to IFN-I production. However, the involvement of STING in the pathogenesis of SLE has not been clarified. We studied the role of STING in the production of IFN-I in SLE.

Methods We evaluated both the IFN-I bioactivity in sera and the serum-mediated type-I IFN-inducing activity (IFN-I-IA) in SLE by using two different reporter cell lines. Also, to address contribution of STING in the production of IFN-I, we established the STING-deficient reporter cell lines (STING-KO) using the CRISPR/Cas9 system.

Results IFN-I bioactivity was high in the sera from SLE compared with other autoimmune diseases and healthy controls. Serum-induced IFN-I-IA was also higher in SLE than those in other autoimmune diseases. These reporter cell lines do not respond to the ligands of Toll like receptor (TLR) 8 or TLR9, suggesting the existence of TLR8/9-independent IFN-I-inducing mechanism. Consistently, the enhanced IFN-I-IA in SLE was reduced in the STING-KO, indicating that STING is involved in the serum-induced IFN-I production.

Conclusions Our finding suggests that IFN-I bioactivity is high in the sera of SLE, and that these sera have a potential to induce IFN-I production through STING.

Parallel Session 9: The mosaic of autoimmunity

26

CLINICAL SIGNIFICANCE OF AUTOANTIBODIES IN MYOSITIS WITH INTERSTITIAL LUNG DISEASE

¹T Mimori*. ¹Kyoto University, Department of Rheumatology and Clinical Immunology, Kyoto, Japan

10.1136/lupus-2017-000215.26

Interstitial lung disease (ILD) is the most frequent organ involvement found in near half of myositis patients, but it